Search
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking.
Decitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … [A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalMutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Foreskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedDermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.
Peginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa … Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label].
Categories: Compounds used in a research, industrial, or household settingProducts: PEGINTRON® PEN 50 MCGDeutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIn clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046]. … This allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043].
Emedastine
go.drugbank.com/drugs/DB01084ApprovedEmedastine is an antihistamine used in eye drops to treat allergic conjunctivitis.
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalCilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. … [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]
Mixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNSucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalIt is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … , peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655].
Categories: Aluminum ComplexFidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigationalfrom week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period. … [A32552] Disease severity is linked to the level of factor IX activity in the blood plasma, ranging from increased bleeding after injuries and surgical operations to spontaneous bleeding, hemorrhages in
Categories: Complex Mixtures